Description

NovoMix 30 FlexPen Suspension for Injections 100 IU/ml. 3 ml Syringe №5

Ingredients:

NovoMix 30 FlexPen contains 100 IU/ml of insulin aspart and insulin aspart protamine. Other ingredients include glycerol, metacresol, zinc chloride, disodium hydrogen phosphate dihydrate, sodium chloride, and water for injections.

Dosage:

The dosage of NovoMix 30 FlexPen should be individualized based on the patient’s needs. It is typically injected subcutaneously 5 to 10 minutes before a meal. Dosage adjustments may be necessary based on blood glucose monitoring.

Indications:

NovoMix 30 FlexPen is indicated for the treatment of diabetes mellitus in adults. It helps control blood sugar levels by regulating glucose metabolism.

Contraindications:

NovoMix 30 FlexPen is contraindicated in patients with hypersensitivity to insulin aspart or any of the excipients. It should not be used during episodes of hypoglycemia.

Directions:

NovoMix 30 FlexPen should be administered as directed by a healthcare provider. It is important to follow the prescribed dosage and injection technique. Rotate injection sites to prevent lipodystrophy.

Scientific Evidence:

Studies have shown that NovoMix 30 FlexPen is effective in controlling postprandial glucose levels and reducing HbA1c levels in patients with type 2 diabetes. Research published in the Journal of Diabetes Science and Technology demonstrated the efficacy and safety of NovoMix 30 in improving glycemic control.

Additional Information:

NovoMix 30 FlexPen offers a convenient and easy-to-use insulin delivery system for patients with diabetes. It provides a rapid onset of action to control postprandial glucose spikes and a prolonged effect to maintain blood sugar levels throughout the day.

Pharmacologically, NovoMix 30 combines the rapid-acting insulin aspart with the long-acting insulin aspart protamine to mimic the physiological insulin profile more closely. This combination provides both immediate and extended glycemic control, offering patients flexibility in managing their diabetes.

Clinical trials have shown that NovoMix 30 FlexPen is comparable in efficacy to other premixed insulin analogs, with a lower risk of hypoglycemia. Patients using NovoMix 30 have reported improved satisfaction with treatment due to its ease of use and effectiveness in controlling blood sugar levels.